GeneVax AI

Executive Summary

GeneVax AI is a Cambridge-based biotechnology company leveraging artificial intelligence and machine learning to revolutionize vaccine and genetic medicine design. Founded in 2021, the company's platform integrates genomics to accelerate the discovery and optimization of novel antigens and therapeutic constructs, targeting infectious diseases, oncology, and genetically-influenced conditions. With $55 million in total raised, GeneVax AI is positioned as a pioneer in AI-driven drug development, aiming to reduce timelines and improve efficacy compared to traditional methods. The company's platform approach allows for rapid adaptation to emerging pathogens and personalized cancer vaccines, addressing significant unmet medical needs. While still in the platform stage, GeneVax AI's innovative technology has attracted substantial investor interest, and its progress in preclinical or early clinical programs could validate its potential to transform the vaccine landscape.

Upcoming Catalysts (preview)

• Q3 2026Major pharmaceutical partnership for infectious disease program75% success
• Q4 2026IND filing for lead oncology candidate60% success
• Q2 2026Series B funding round exceeding $100 million80% success